Evidence map›Paper›PMID 42836734›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Clusterin is enriched in plaque-associated astrocytes and localizes to synapses in Alzheimer's disease.

Robert A J Byrne, Aurora Veteleanu, Hannah L Cramp, Olivia G Bacon, Kirsten L Baillie, Matthew Bright, Rebekah S Cooke, Gareth D Fenn, Mariana Flores Castelán, Kok Yung Lee and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clusterin is enriched in plaque-associated astrocytes and localizes to synapses in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Robert A J ByrneUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Aurora VeteleanuUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Hannah L CrampUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Olivia G BaconUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Kirsten L BaillieHodge Centre for Translational Neuroscience, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Matthew BrightUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Rebekah S CookeUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Gareth D FennUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Mariana Flores CastelánUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Kok Yung LeeUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Wioleta M ZelekUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
B Paul MorganUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Nikoleta DaskoulidouUK Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, Wales, UK.ORCID https://orcid.org/0000-0002-7782-1232

Funding

Alzheimer's Research UK 520488UK Research and Innovation UK DRI-3002
6 · The paper itself

Abstract

introductionThe clusterin gene (CLU) is a top genome-wide association studies (GWAS) risk locus for Alzheimer's disease (AD) and elevated clusterin levels have been reported in AD biofluids and brain tissue. Despite growing interest in clusterin as a biomarker and therapeutic target, its cellular and subcellular localization in the human brain remains incompletely understood, in part due to a lack of well-characterized reagents.

methodsWe generated and validated monoclonal antibodies (mAbs) that distinguish secreted and intracellular clusterin, and applied these tools to human biofluids, brain tissue, and induced pluripotent stem cell (iPSC) -derived astrocytes.

resultsThe mAbs enabled sensitive detection and quantification of clusterin in plasma, serum, cerebrospinal fluid, and brain tissue homogenates. Immunostaining demonstrated that clusterin is associated with amyloid plaques in AD brain and localizes to synapses in both healthy and AD tissue; the mAb detecting intracellular clusterin demonstrated specific expression in astrocytes, confirmed using astrocytoma lines and iPSC-derived astrocytes. Quantitative analysis demonstrated increased clusterin signal in plaque-associated astrocytes, particularly those surrounding larger plaques. DISCUSSION: The findings provide better understanding of clusterin expression in the healthy and AD brain, informing roles of clusterin in brain homeostasis and AD pathogenesis.

Indexed as

Alzheimer DiseaseAstrocytesClusterinPlaque, AmyloidSynapsesAnimalsAntibodies, MonoclonalBrainHumansInduced Pluripotent Stem CellsAntibodies, MonoclonalCLU protein, humanClusterinAlzheimer's diseaseastrocytesclusterincomplementimmunoassaymonoclonal antibodysynapses

Identifiers

PMID42836734
PMCPMC13640977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.